LB: a useful pharmabiotic for the treatment of digestive disorders
Abstrak
Dysbiosis, a loss of balance between resident bacterial communities and their host, is associated with multiple diseases, including inflammatory bowel diseases (nonspecific chronic ulcerative colitis and Crohn’s disease), and digestive functional disorders. Probiotics, prebiotics, synbiotic organisms and, more recently, pharmabiotics, have been shown to modulate the human microbiota. In this review, we provide an overview of the key concepts relating to probiotics, prebiotics, synbiotic organisms, and pharmabiotics, with a focus on available clinical evidence regarding the specific use of a unique pharmabiotic, the strain Lactobacillus acidophilus LB ( Lactobacillus boucardii ), for the management of gastrointestinal disorders. Since it does not contain living organisms, the administration of L. acidophilus LB is effective and safe as an adjuvant in the treatment of acute diarrhea, chronic diarrhea, and antibiotic-associated diarrhea, even in the presence of immunosuppression.
Topik & Kata Kunci
Penulis (14)
José María Remes-Troche
Enrique Coss-Adame
Miguel Ángel Valdovinos-Díaz
Octavio Gómez-Escudero
María Eugenia Icaza-Chávez
José Antonio Chávez-Barrera
Flora Zárate-Mondragón
José Antonio Velarde-Ruíz Velasco
Guillermo Rafael Aceves-Tavares
Marco Antonio Lira-Pedrín
Eduardo Cerda-Contreras
Ramón Isaías Carmona-Sánchez
Héctor Guerra López
Rodolfo Solana Ortiz
Akses Cepat
- Tahun Terbit
- 2020
- Sumber Database
- DOAJ
- DOI
- 10.1177/1756284820971201
- Akses
- Open Access ✓